全身性エリテマトーデス治療のための生物学的製剤の安全性および有効性に関する研究

基本情報

NCT ID

NCT02265744

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

730

治験依頼者名

Bristol-Myers Squibb

概要

Study evaluating the safety and efficacy of a novel biologic in the treatment of systemic lupus erythematosus in male and female adults. Patients who qualify will be randomized to either active BMS-931699 or placebo for initially, up to 24 weeks. Patients who complete the initial 24 weeks of treatment and who are responding to therapy will have the option to continue receiving BMS-931699 as part of a long-term extension (LTE). Disease activity and safety will be assessed over the course of the study through laboratory values, various rating scales accepted in systemic lupus erythematosus studies and patient self reporting.

対象疾患

介入

依頼者（Sponsor）